Clinical Study

Hippocampal Atrophy in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations

Table 4

Correlations between HIPV/HIPD and clinical characteristics.

LHIPVRHIPVLHIPDRHIPD
rprprprp

Disease duration (m)-0.1930.082-0.1150.302-0.1410.192-0.1360.222
Urine protein (g/d)-0.300-0.255-0.272-0.247
SLEDAI-0.239-0.245-0.1830.090-0.221
Total GC (g)-0.2150.053-0.1270.256-0.2040.058-0.1480.183
Total HCQ (g)0.1110.3200.2540.0240.8250.0690.537
Total CTX (g)-0.0470.674-0.0830.457-0.0520.635-0.0350.755
HAMD0.0040.9690.0100.929-0.0280.799-0.0050.965
HAMA-0.0220.8440.0560.616-0.0350.7450.0450.688

L: left; HIPV: hippocampal volume; R: right; HIPD: hippocampal density; SLICC: Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for Systemic Lupus Erythematosus; SLEDAI: systemic lupus erythematosus disease activity index; GC: glucocorticoid; HCQ: hydroxychloroquine; CTX: cyclophosphamide. , .